Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

February 18, 2023 updated by: Erin Barreto, Mayo Clinic

Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill: a Multicenter Mixed-methods Study

The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

138

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Queensland
      • Herston, Queensland, Australia, 4029
        • Royal Brisbane and Women's Hospital
    • Florida
      • Gainesville, Florida, United States, 32610
        • UF Health Shands
    • Minnesota
      • Rochester, Minnesota, United States, 55902
        • Mayo Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Data will be obtained from ICU clinicians at three hospitals with distinct beta-lactam dosing and monitoring practices: Royal Brisbane and Women's Hospital in Queensland Australia, University of Florida Health Shands Hospital, Gainesville, Florida, United States, and the Mayo Clinic Hospital in Rochester, Minnesota, United States. The sampling frame will include key clinician stakeholders likely to be involved with beta-lactam TDM in the intensive care unit (i.e., pharmacists, intensivists, infectious diseases experts, medical/surgical trainees, and advanced practice providers).

Description

Inclusion Criteria:

  • Providers involved with beta-lactam TDM for critically ill patients

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of drug level testing recommended
Time Frame: Baseline
Indication of how many critically ill patients treated with beta-lactams should receive TDM.
Baseline
Nature of drug level testing recommended
Time Frame: Baseline
Indication of which types of critically ill patients treated with beta-lactams should receive TDM
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determinants of beta-lactam TDM implementation
Time Frame: Baseline
List of factors associated with successful beta-lactam TDM implementation
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 22, 2020

Primary Completion (Actual)

December 31, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

February 10, 2021

First Submitted That Met QC Criteria

February 12, 2021

First Posted (Actual)

February 16, 2021

Study Record Updates

Last Update Posted (Estimate)

February 21, 2023

Last Update Submitted That Met QC Criteria

February 18, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe